Gang Niu1, Zibo Li, Qizhen Cao, Xiaoyuan Chen. 1. The Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University School of Medicine, 1201 Welch Rd, P095, Stanford, CA 94305-5484, USA.
Abstract
PURPOSE: 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat-shock protein 90 (Hsp90) inhibitor, has been intensively investigated for cancer therapy and is undergoing clinical trials. Human epidermal growth factor receptor 2 (HER-2) is one of the client proteins of Hsp90 and its expression is decreased upon 17-DMAG treatment. In this study, we aimed to noninvasively monitor the HER-2 response to 17-DMAG treatment in xenografted mice. METHODS: The sensitivity of human ovarian cancer SKOV-3 cells to 17-DMAG in vitro was measured by MTT assay. HER-2 expression in SKOV-3 cells was determined by flow cytometry. Nude mice bearing SKOV-3 tumors were treated with 17-DMAG and the therapeutic efficacy was evaluated by tumor size measurement. Both treated and control mice were imaged with microPET using (64)Cu-DOTA-trastuzumab and (18)F-FDG. Biodistribution studies and immunofluorescence staining were performed to validate the microPET results. RESULTS: SKOV-3 cells are sensitive to 17-DMAG treatment, in a dose-dependent manner, with an IC(50) value of 24.72 nM after 72 h incubation. The tumor growth curve supported the inhibition effect of 17-DMAG on SKOV-3 tumors. Quantitative microPET imaging showed that (64)Cu-DOTA-trastuzumab had prominent tumor accumulation in untreated SKOV-3 tumors, which was significantly reduced in 17-DMAG-treated tumors. There was no uptake difference detected by FDG PET. Immunofluorescence staining confirmed the significant reduction in tumor HER-2 level upon 17-DMAG treatment. CONCLUSION: The early response to anti-Hsp90 therapy was successfully monitored by quantitative PET using (64)Cu-DOTA-trastuzumab. This approach may be valuable in monitoring the therapeutic response in HER-2-positive cancer patients under 17-DMAG treatment.
PURPOSE:17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat-shock protein 90 (Hsp90) inhibitor, has been intensively investigated for cancer therapy and is undergoing clinical trials. Human epidermal growth factor receptor 2 (HER-2) is one of the client proteins of Hsp90 and its expression is decreased upon 17-DMAG treatment. In this study, we aimed to noninvasively monitor the HER-2 response to 17-DMAG treatment in xenografted mice. METHODS: The sensitivity of humanovarian cancerSKOV-3 cells to 17-DMAG in vitro was measured by MTT assay. HER-2 expression in SKOV-3 cells was determined by flow cytometry. Nude mice bearing SKOV-3 tumors were treated with 17-DMAG and the therapeutic efficacy was evaluated by tumor size measurement. Both treated and control mice were imaged with microPET using (64)Cu-DOTA-trastuzumab and (18)F-FDG. Biodistribution studies and immunofluorescence staining were performed to validate the microPET results. RESULTS:SKOV-3 cells are sensitive to 17-DMAG treatment, in a dose-dependent manner, with an IC(50) value of 24.72 nM after 72 h incubation. The tumor growth curve supported the inhibition effect of 17-DMAG on SKOV-3 tumors. Quantitative microPET imaging showed that (64)Cu-DOTA-trastuzumab had prominent tumor accumulation in untreated SKOV-3 tumors, which was significantly reduced in 17-DMAG-treated tumors. There was no uptake difference detected by FDG PET. Immunofluorescence staining confirmed the significant reduction in tumorHER-2 level upon 17-DMAG treatment. CONCLUSION: The early response to anti-Hsp90 therapy was successfully monitored by quantitative PET using (64)Cu-DOTA-trastuzumab. This approach may be valuable in monitoring the therapeutic response in HER-2-positive cancerpatients under 17-DMAG treatment.
Authors: P A Clarke; I Hostein; U Banerji; F D Stefano; A Maloney; M Walton; I Judson; P Workman Journal: Oncogene Date: 2000-08-24 Impact factor: 9.867
Authors: R C Bast; P Ravdin; D F Hayes; S Bates; H Fritsche; J M Jessup; N Kemeny; G Y Locker; R G Mennel; M R Somerfield Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: David B Solit; Iman Osman; David Polsky; Katherine S Panageas; Adil Daud; James S Goydos; Jerrold Teitcher; Jedd D Wolchok; F Joseph Germino; Susan E Krown; Daniel Coit; Neal Rosen; Paul B Chapman Journal: Clin Cancer Res Date: 2008-12-15 Impact factor: 12.531
Authors: Malcolm A Smith; Christopher L Morton; Doris A Phelps; E Anders Kolb; Richard Lock; Hernan Carol; C Patrick Reynolds; John M Maris; Stephen T Keir; Jianrong Wu; Peter J Houghton Journal: Pediatr Blood Cancer Date: 2008-07 Impact factor: 3.167
Authors: Diane E Milenic; Karen J Wong; Kwamena E Baidoo; Tapan K Nayak; Celeste A S Regino; Kayhan Garmestani; Martin W Brechbiel Journal: MAbs Date: 2010-09-01 Impact factor: 5.857
Authors: Gang Ren; Jack M Webster; Zhe Liu; Rong Zhang; Zheng Miao; Hongguang Liu; Sanjiv S Gambhir; Faisal A Syud; Zhen Cheng Journal: Amino Acids Date: 2011-10-08 Impact factor: 3.520
Authors: Jason P Holland; Eloisi Caldas-Lopes; Vadim Divilov; Valerie A Longo; Tony Taldone; Danuta Zatorska; Gabriela Chiosis; Jason S Lewis Journal: PLoS One Date: 2010-01-25 Impact factor: 3.240
Authors: Shivaani Kummar; Martin E Gutierrez; Erin R Gardner; Xiaohong Chen; William D Figg; Maria Zajac-Kaye; Min Chen; Seth M Steinberg; Christine A Muir; Mary Ann Yancey; Yvonne R Horneffer; Lamin Juwara; Giovanni Melillo; S Percy Ivy; Maria Merino; Len Neckers; Patricia S Steeg; Barbara A Conley; Giuseppe Giaccone; James H Doroshow; Anthony J Murgo Journal: Eur J Cancer Date: 2009-11-27 Impact factor: 9.162